Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341613 | 0.85 | DHFR (0.45) | DHFRCASRKCNH2ALDH1A1HTT | |
| SCHEMBL24944395 | 0.75 | HSP90AA1 (0.36) | KCNH2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL24944392 | 0.75 | CCR9 (0.36) | KCNH2 | |
| SCHEMBL21341730 | 0.74 | KCNH2 (0.35) | DHFRCASRKCNH2ALDH1A1HTT | |
| SCHEMBL24944390 | 0.72 | — | — | |
| SCHEMBL21341614 | 0.71 | KCNH2 (0.38) | DHFRKCNH2ALDH1A1 | |
| SCHEMBL19383164 | 0.68 | ALDH1A1 (0.38) | DHFRCASRKCNH2ALDH1A1HTT | |
| SCHEMBL24943616 | 0.68 | CCR9 (0.33) | KCNH2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20618778 | 0.66 | KCNH2 (0.41) | KCNH2ALDH1A1 | |
| SCHEMBL21341616 | 0.66 | CCR9 (0.38) | KCNH2ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | DHFR 1618/4885CASR 4355/4885KCNH2 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.